Methods and compositions for determining the efficacy of therapeutic cell compositions

By contacting FC and/or alpha beta TCR+ T cell samples with mitotic stimuli and detecting the phosphorylation of ribosomal S6 protein, the problem of difficulty in evaluating the efficacy of therapeutic cell compositions in the prior art is solved, and rapid , quantitative efficacy evaluation and therapeutic dose indication ensure the biological quality and stability of the cellular composition.

CN111373259BActive Publication Date: 2024-11-26TALARIS THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880025382.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-03-06
Filing Date
2018-03-06
Publication Date
2024-11-26
Estimated Expiration
2038-11-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively evaluate and determine the therapeutic efficacy of pro-transplant cells (FCs) and alpha beta TCR+ T cells in therapeutic cell compositions, especially in the complex biological pathways and biological function associations, making it difficult to achieve production batches. Effectiveness determination of inter-sequence consistency.

Method used

By contacting FC and/or alpha beta TCR+ T cell samples with mitotic stimuli and determining phosphorylation of ribosomal S6 protein in the sample, fluorescently labeled antibodies and FACS assays are used to evaluate cell potency, providing rapid and quantitative method.

Benefits of technology

A rapid and quantitative assessment of the efficacy of FC and alpha beta TCR+ T cells is achieved, ensuring the biological quality and stability of therapeutic cell compositions, providing appropriate therapeutic dose indications, suitable for applications in clinical settings.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0002235587990000081
    Figure GDA0002235587990000081
  • Figure GDA0002235587990000091
    Figure GDA0002235587990000091
  • Figure GDA0002235587990000101
    Figure GDA0002235587990000101
Patent Text Reader

Abstract

The present disclosure provides potency assays for assessing the potency of booster cells and / or alpha beta TCR+ T cells.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 467,420, filed March 6, 2017, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] Generally, the present disclosure relates to methods and compositions for determining the efficacy of therapeutic cellular compositions. Background of the Invention

[0005] The efficacy assay is intended to predict the therapeutic activity of a cell composition by detecting or measuring one or more biomarkers associated with one or more physiological properties. However, since the therapeutic mechanism of action can vary between therapeutic cell compositions, it may be difficult to identify biological functions that are reproducibly associated with related biological or biophysical properties. In addition, since the therapeutic mechanism of action can rely on complex biological pathways, it may be particularly challenging to determine which product attributes are most relevant to determining efficacy. Nevertheless, it is extremely important to develop an efficacy assay that reflects the therapeutic properties of a cell composition and provides reliable measurements of consistency between production batches.

[0006] The present disclosure describes a novel potency assay for evaluating the therapeutic efficacy of engraftment-promoting cells (FC) and / or alpha beta TCR+ T cells. SUMMARY OF THE INVENTION

[0008] Described herein are methods and compositions for evaluating the potency of booster cells and / or alpha beta TCR+ T cells.

[0009] In one aspect, methods for determining the potency of a sample comprising facilitating cells (FC) and / or alpha beta TCR+T cells are provided. Such methods typically include contacting a sample comprising FC and / or alpha beta TCR+T cells with a mitogenic stimulus; and determining the number of FC and / or alpha beta TCR+T cells in the sample whose ribosomal S6 protein is phosphorylated (pS6). As described herein, the number of FC and / or alpha beta TCR+T cells in the sample whose pS6 is phosphorylated indicates the potency of FC and / or alpha beta TCR+T cells, respectively, in the sample.

[0010] Representative mitogenic stimulants include, but are not limited to, phorbol 12-myristate 13-acetate (PMA) and ionomycin, phytohemagglutinin (PHA), concanavalin A (conA) and pokeweed mitogen (PWM). In some embodiments, the sample is contacted with the mitogenic stimulant for a period of about 5 minutes to about 60 minutes (e.g., about 20 minutes to about 30 minutes).

[0011] In some embodiments, the sample includes about 100,000 to about 2,000,000 FC and / or alpha beta TCR+ T cells. In some embodiments, the number of FC and / or alpha beta TCR+ T cells in which pS6 is phosphorylated in the sample is determined using a fluorescently labeled antibody directed against pS6. In some embodiments, the binding of the fluorescently labeled antibody is detected using FACS.

[0012] In some embodiments, the method is performed prior to freezing the FC and / or alpha beta TCR+ T cells. In some embodiments, the method is performed on FC and / or alpha beta TCR+ T cells that have been frozen.

[0013] In some embodiments, at least 30% of the FCs in the sample are pS6+. In some embodiments, at least 30% of the alpha beta TCR+ T cells in the sample are pS6+.

[0014] In another aspect, methods for determining a therapeutic dose of FC and / or alpha beta TCR+T cells are provided. Such methods typically include providing a cell sample including FC and / or alpha beta TCR+T cells; determining the potency of the cell sample. As described herein, the potency of the cell sample can be an indication of a therapeutic dose of FC and / or alpha beta TCR+T cells.

[0015] In another aspect, a preparation comprising an antibody against a phosphorylated form of pS6 and at least one of: an antibody against CD3, an antibody against CD8, and an antibody against alpha beta TCR.

[0016] In some embodiments, the preparation includes an antibody to a phosphorylated form of pS6, an antibody to CD3, and an antibody to the alpha beta T cell receptor (TCR). In some embodiments, the preparation includes an antibody to a phosphorylated form of pS6 and an antibody to CD8. In some embodiments, the preparation includes an antibody to a phosphorylated form of pS6, an antibody to CD3, an antibody to CD8, and an antibody to the alpha beta TCR.

[0017] The articles as described herein may further include a mitogenic stimulus. The articles as described herein may further include at least one fluorescent label. The articles as described herein may further include at least one fluorescent label for each antibody. In some embodiments, each of the at least one fluorescent label for each antibody is distinguishable from each other.

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those of ordinary skill in the field to which the composition of the method and substance belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the composition of the method and substance, suitable methods and materials are as described below. In addition, materials, methods and embodiments are only illustrative and are not intended to be limiting. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Gating for FC (CD8+ / TCR-) is shown.

[0020] Figure 2 It is a graph showing the selectivity of pS6 for FC.

[0021] Figure 3 Gating of alpha beta TCR+ cells is shown.

[0022] Figure 4 is a graph showing the selectivity of pS6 for alpha beta TCR+ cells.

[0023] Figure 5 A linear fit of pS6+ versus FC is shown. DETAILED DESCRIPTION OF THE INVENTION

[0025] The present disclosure provides methods for determining the potency of FC and / or alpha beta TCR+T cells. FC and alphabeta TCR+T cells are two of the three main components in therapeutic cell compositions, which are described in U.S. Pat. Nos. 8,632,768 and 9,452,184. Considering the current therapeutic and clinical uses of the therapeutic cell compositions, a rapid and quantitative method for evaluating the potency of the therapeutic cell compositions, and more specifically the FC and alphabeta TCR+T cells therein, after preparation and before administration to a patient would be very useful.

[0026] During the preparation of therapeutic compositions of HSC, FC and alpha beta TCR+T cells, or after such therapeutic compositions have been prepared, a sample of cells can be taken out of the composition and contacted with a mitogenic stimulant. Typically, FC and / or alpha beta TCR+T cells (e.g., about 100,000 to 2,000,000 FC and / or alpha beta TCR+T cells) are contacted with a mitogenic stimulant. As used herein, a mitogenic stimulant or simply referred to as a mitogen refers to a compound (e.g., protein, small molecule, etc.) that triggers cells to undergo mitosis. Representative mitogenic stimulants include, but are not limited to, phorbol 12-myristate 13-acetate (PMA; also known as 12-O-tetradecanoylphorbol-13-acetate (TPA)) with ionomycin, phytohemagglutinin (PHA), concanavalin A (conA) or pokeweed mitogen (PWM). In some cases, a commercially available cell stimulatory cocktail (e.g., catalog number 00-4970, ThermoFisher Scientific) can be used under the manufacturer's conditions. Alternatively, dilution or titration experiments can be performed to determine the amount and duration of exposure of a particular mitogen that produces the greatest amount of stimulation and / or a signal indicative of efficacy in a therapeutic cell composition as described herein.

[0027] Typically, about 100,000 to about 2,000,000 total cells (i.e., from a therapeutic cell composition comprising HSCs, FCs, and alpha beta TCR+ T cells) are contacted with a mitogen, mixed thoroughly (e.g., vortexed), and maintained at a temperature of about 37°C for about 5 minutes to about 60 minutes (i.e., one hour) (e.g., about 5 minutes to about 50 minutes; about 5 minutes to about 30 minutes; about 5 minutes to about 15 minutes; about 10 minutes to about 45 minutes; about 10 minutes to about 30 minutes; about 15 minutes to about 45 minutes; about 15 minutes to about 30 minutes; about 20 minutes to about 60 minutes; about 20 minutes to about 40 minutes; about 30 minutes to about 45 minutes; about 30 minutes to about 60 minutes; about 45 minutes to about 60 minutes). The length of time that the FC and / or alpha beta TCR+ T cells are exposed to the mitogenic stimulus depends in part on the specific mitogenic stimulus used; in some embodiments, the FC and / or alpha beta TCR+ T cells are exposed to the mitogenic stimulus for about 15 minutes in a 5% CO2 incubator set at 37°C.

[0028] After stimulating the cells with a mitogen for an appropriate length of time, the number of FC and / or alpha beta TCR+T cells whose ribosomal S6 protein "(S6") is phosphorylated ("pS6") is determined. It should be understood that the most common and effective method for determining the number of cells is to use one or more fluorescent antibodies and fluorescence activated cell sorting (FACS) analysis. In the present method, differentially fluorescently labeled antibodies can be used to stain stimulated cells with anti-CD3, anti-CD8, anti-alpha beta TCR, and anti-phospho-S6 (i.e., anti-pS6). The total FC is calculated as CD8+ and alpha beta TCR-, while the effective FC is calculated as CD8+, alpha beta TCR-, and phosphorylated S6+ (i.e., pS6+). Similarly, the total alpha beta TCR+T cells are calculated as CD3+, while the effective alpha beta TCR+T cells are calculated as CD3+ and pS6+. Antibodies that can be used in the methods described herein are commercially available. See, e.g., BD Biosciences (e.g., Catalog Nos. 563423; 557757; 555916; 557760; 557746; 561951; 563625; 563826; 561674; 560433; 560434; or 560435); Abnova Corp. (e.g., Catalog Nos. MAB12370; MAB9820; MAB4591; MAB4596; ab99859; ab95648; MAB6560; or MAB6559); or eBiosciences (e.g., Catalog Nos. 12-0039; 50-0037; 25-0087; 9047-0087; 46-9986; 11-9986; 12-9007; or 48-9007).

[0029] A large number of fluorescent labels that can be used with FACS are known in the art. A large number of different labels (can be classified by the wavelength of the light (e.g., red, purple, yellow, green, blue) they emit) allow for simultaneous or parallel detection of multiple antibodies and their corresponding binding targets. For example, antibodies for CD3, CD8, and alpha beta TCR as described herein can be differentially labeled so that FC can be distinguished from alpha beta TCR+T cells, and antibodies for the phosphorylated form of pS6 can also be differentially labeled with other labeled antibodies so that phosphorylated S6 (i.e., pS6) can be distinguished from non-phosphorylated S6FC and phosphorylated S6 (i.e., pS6) can be distinguished from non-phosphorylated S6alpha beta TCR+T cells. Without limitation, representative fluorescent labels include, for example, Alexa fluor 488, Alexa fluor 532, Alexa fluor 647, Alexa fluor 700, Cyanine 5, Cyanine 5.5, Cyanine 7, fluorescent isothiocyanate (FITC), phycoerythrin (PE), eFluor 450, eFluor 506, eFluor 610, eFluor 660, and eFluor 780. Fluorescent labels can be obtained, for example, from EMD Millipore (Darmstadt, Germany); abcam (Cambridge, Cambridgeshire, UK); and Promega (Madison, WI).

[0030] For example, in a GMP (Good Manufacturing Practice) production environment for clinical use, a small portion of the final therapeutic cell composition can be contacted with a mitogenic stimulus for an appropriate period of time and then analyzed by FACS to determine the percentage of FC and alpha beta TCR+ cells containing pS6. In some embodiments, about six million white blood cells are stimulated with a mitogen. Typically, of 6 million white blood cells, about 250,000 cells are expected to be alpha beta TCR+T cells, while about 25,000 cells are expected to be FC. The sample can be evaluated before cryopreservation and / or after cryopreservation and thawing. In the latter case, the sample to be evaluated for efficacy can be cryopreserved in a separate vial. Efficacy testing can be performed before the patient is ready to receive the therapeutic cell composition administration, and can be used to determine whether the therapeutic cell composition has enough cells for administration. The methods for determining the efficacy of FC and / or alpha beta TCR+T cells described herein are quantitative and can be performed within about 2 to 4 hours, which makes these methods very useful in clinical settings.

[0031] As described herein, the number of FC and / or alpha beta TCR+T cells in a sample in which S6 has been phosphorylated is an indicator of the potency of those cells in the sample. As used herein, "potency" refers to the number of cells in a sample that respond to mitogenic stimuli by phosphorylating S6. Cells that respond in this manner (i.e., by phosphorylating S6) are considered to be effective because they can respond to extracellular signals and initiate nuclear reprogramming in response to these signals. Determining the potency of cells (e.g., FC and alpha beta TCR+T cells) after preparation and / or any other type of operation (e.g., freezing, thawing, shipping / delivery) may be a key component in preparing therapeutic cell compositions and determining the biological quality of therapeutic cell compositions. Importantly, the potency assays described herein can also be used to determine and quantify the stability of therapeutic cell compositions during and / or after storage (e.g., cryopreservation).

[0032] For cell therapy, it is desirable to confirm or determine the potency of one or more cell types in a cell composition. In the present case, it is desirable that at least about 30% of the FC in the cell composition is pS6+ (i.e., at least about 30% of the FC in the sample is potent) or at least about 30% of the alpha beta TCR+ T cells in the cell composition are pS6+ (i.e., at least about 30% of the alpha beta TCR+ T cells in the sample are potent). In the present case, it is desirable that at least about 30% of the FC in the cell composition is pS6+ (i.e., at least about 30% of the FC in the sample is potent) and at least about 30% of the alpha beta TCR+ T cells in the cell composition are pS6+ (i.e., at least about 30% of the alpha beta TCR+ T cells in the sample are potent).

[0033] It should be understood that, as used herein, "at least 30%" with respect to a therapeutic cell composition or any particular cell type therein can refer to, for example, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. It should also be understood that reference to at least 30% can refer to, for example, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 50% to about 80%, about 50% to about 70%, about 60% to about 90%, about 60% to about 80%, about 70% to about 80%, about 75% to about 80%, or about 80% to about 90%.

[0034] In some cases, one or more documents (e.g., a certificate of analysis) may accompany the therapeutic cell composition. The documents that may be included with the therapeutic cell composition may report, for example, one or more of the following: the total percentage of pS6+ or effective cells in the therapeutic cell composition (relative to the total number of cells); the percentage of pS6+ or effective FCs in the therapeutic cell composition; the percentage of pS6+ or effective alpha beta TCR+T cells in the therapeutic cell composition; the number of pS6+ or effective FCs in the therapeutic cell composition; and / or the number of pS6+ or effective alpha beta TCR+T cells in the therapeutic cell composition. The documents that may be included with the therapeutic cell composition may also indicate a recommended dose (e.g., total cell count, pS6+ or effective cell count or volume) and / or a dosing regimen.

[0035] Thus, the methods described herein can be used to determine a suitable therapeutic dose of a cell composition comprising FC and / or alpha beta TCR+T cells. For example, the potency of a cell sample comprising FC and / or alpha beta TCR+T cells can be determined as described herein, and a therapeutic dose is determined based on the potency of one or both of the FC or alpha beta TCR+T cells and subsequently administered to a patient. As used herein, a suitable therapeutic dose refers to a dose that allows transplantation in the absence of graft-versus-host disease and in the absence of any toxicity (e.g., from alpha beta TCR+T cells).

[0036] The present disclosure also provides articles of manufacture. Articles of manufacture as described herein may include, for example, one or more antibodies as described herein. For example, one or more antibodies that specifically bind to CD3, CD8, alpha beta TCR and / or pS6 may be included in articles of manufacture as described herein.

[0037] The articles as described herein may also include one or more fluorescent labels. It should be understood that a fluorescent label may be provided for each of the antibodies in the article. It should also be understood that when a fluorescent label is provided for each of the antibodies, each of those fluorescent labels may be different (e.g., distinguishable from each other). In addition, one or more antibodies in the article may be provided already labeled; alternatively, the fluorescent label may be provided separately from the antibody (e.g., in a separate vial) for labeling by the end user.

[0038] The article of manufacture may include other components, such as, but not limited to, one or more mitogens (e.g., phorbol 12-myristate 13-acetate (PMA) with ionomycin, phytohemagglutinin (PHA), concanavalin A (conA), or pokeweed mitogen (PWM)), cell culture medium, one or more buffers, reagents, and / or cofactors. The article of manufacture may also include one or more containers, such as vials, cuvettes, test tubes, culture plates, etc., for performing the steps necessary to determine the potency of FC and / or alpha beta TCR+T cells.

[0039] According to the present invention, conventional molecular biology, microbiology, biochemistry and recombinant DNA techniques can be used within the technical scope of the art. Such techniques are fully explained in the literature. The present invention will be further described in the following examples, which do not limit the scope of the composition of methods and materials described in the claims. Example

[0040] Example 1 - Principle of the method

[0041] The methods described herein can be used to determine the potency of the cryopreserved final product from the manufacturing process of the therapeutic cell composition referred to herein as FCRx.

[0042] Promoter cells (FC) and alpha beta TCR + The mechanism of action of cells is a complex process involving cell migration, support of stem cell transplantation, and the development of immune tolerance. Phosphorylation of the target ribosomal S6 protein (pS6) involved in protein synthesis and cell proliferation was developed as a surrogate assay to indicate FC and alpha beta TCR + Cells are able to respond to mitogenic stimuli after cryopreservation. + Phosphorylation of S6 was quantified in unstimulated and stimulated cell samples stained with a panel of antibodies and the increase in pS6 upon stimulation was determined for both cell subsets.

[0043] Immunophenotyping is a technique used to study the proteins expressed by cells. It involves labeling cells with fluorescent antibodies against cell surface antigens or intracellular proteins. The labeled cells are analyzed on a flow cytometer, a laser-based instrument capable of analyzing thousands of cells per second in terms of size, cellular complexity, and fluorescent properties.

[0044] T cells display CD3 on their cell surface. A positive fluorescent signal was detected by using a mouse anti-human CD3 antibody labeled with phycoerythrin (PE). The CD8 T cell subset expresses CD8 on its cell surface. A positive fluorescent signal was detected by using a mouse anti-human CD8 antibody labeled with PE. T cells display TCR (composed of alpha beta and gamma delta subunits) on their cell surface. A positive fluorescent signal was detected when labeled with a mouse anti-human alpha beta TCR antibody conjugated with fluorescein isothiocyanate (FITC). A positive fluorescent signal was detected when labeled with a mouse anti-human gamma deltaTCR antibody conjugated with FITC. alpha beta TCR + Cells exhibiting phenotype alpha beta TCR + CD3 + Promoter cells (FC) exhibit the phenotype alpha beta TCR-gamma delta TCR-CD8 + The stimulated cells expressed pS6 in the cells. The positive fluorescence signal was detected by using an anti-pS6 antibody labeled with alexa fluor 647 (AF647).

[0045] FC and alpha beta TCR + Immunophenotyping of cells has been described. See, e.g., U.S. Pat. Nos. 8,632,768 and 9,452,184. Therefore, the present disclosure focuses on using phosphorylation of S6 as an indicator of potency of FC and alpha beta TCR+ T cells.

[0046] The assessment strategy utilized cryopreserved final product from a training run of the FCRx manufacturing process (Lot ICT-R&D052615). Samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences) that had been assessed for acceptable setup, operation, and performance.

[0047] The pS6 assay can be assessed without the use of a positive control (PC) or system suitability test (SST). Typically, the PC or SST would be human cells stimulated with a mitogen and the intracellular pS6 signal measured. However, the FCRx samples contained a heterogeneous mixture of cells, and we analyzed the phenotype of a specific cell subset of interest and evaluated pS6 staining after mitogenic stimulation; therefore, the test sample served as its own SST.

[0048] Additionally, differences in PC responses were also a factor due to donor variability and specific PCs were not available from commercial suppliers. The use and implementation of the assay PC or SST was further investigated during full validation but did not impact the assessment of the efficacy of the pS6 assay for evaluation of the FCRx final product.

[0049] The following abbreviations are used:

[0050] Table 1. Abbreviations

[0051]

[0052]

[0053] Example 2—Selectivity of pS6

[0054] The selectivity of the pS6 antibody was evaluated using the FCRx final product to confirm that negative and positive fluorescence signals were obtained from unstimulated and stimulated cells, respectively. Since unstimulated cells exhibit low levels of S6 phosphorylation (i.e., pS6), selectivity was also evaluated by the increase in pS6 phosphorylation in stimulated cells. The selectivity of the pS6 antibody was evaluated by comparing the unstimulated sample (blue curve) with the stimulated sample (blue curve) ( Figure 2 ) compared to the stimulated samples (red curve), the frequency of FC cells stained for pS6 increased ( Figure 1 ) shows the selectivity of the pS6 antibody by comparing it with the unstimulated sample (blue curve) ( Figure 4 ) compared to alpha beta TCR stained for pS6 in stimulated samples (red curve) + The frequency of cell increase ( Figure 3 )show.

[0055] refer to Figure 1 , FC clearly uses the phenotype alpha beta TCR-gamma delta TCR - CD8 + FC pS6 staining was then evaluated using single parameter histograms.

[0056] refer to Figure 2 , Representative overlay of fluorescence distribution of unstimulated FC (blue curve) and stimulated FC (red curve) stained with pS6. Stimulated cells stained with pS6 antibody show similar fluorescence distribution to pS6. - pS6 + Clear separation of fluorescence intensity of cells (>1 log). Unstimulated sample had 24.81% pS6 +The cells had a mean fluorescence intensity (MFI) of 5.8. The stimulated sample had 78.94% pS6 + The cells, where the MFI was 89.1, showed fluorescence with pS6 - The cells increased 15-fold.

[0057] refer to Figure 3 , alpha beta TCR + Cells clearly phenotyped with alpha beta TCR + / CD3 + The alpha beta TCRs were then evaluated using single parameter histograms. + pS6 staining of cells.

[0058] refer to Figure 4 , Unstimulated alpha beta TCR stained with pS6 + Cells (blue curve) and stimulated alpha beta TCR + Representative overlay of fluorescence distribution of cells (red curve). Stimulated cells stained with pS6 antibody show similar fluorescence distribution to pS6. - pS6 + Clear separation of fluorescence intensity of cells (>1 log). Unstimulated sample had 4.98% pS6 + cells, where the MFI was 5.27. The stimulated sample had 81.47% pS6 + The cells, where the MFI was 62.99, showed fluorescence with pS6 - The cells increased 12-fold.

[0059] These data met the acceptance criteria for selectivity and demonstrated that the assay is specific for pS6.

[0060] Example 3 - Accuracy of the method

[0061] The accuracy of the pS6 assay was determined by the recovery of cells through linearity assessment. The results from linearity (Table 5) were used to show that pS6 + FC data (Table 2).

[0062] Table 2. Accuracy pS6-FC

[0063]

[0064] pS6 + The recovery rate of FC cells ranged from pS6 +94.8% to 116.1% of the FC cell population (range 62.1% to 0.49% of the FC subset). This indicates that the pS6 assay has an accuracy within 16.1% of the nominal value. This meets the goal of calculating a value of ±30% for %pS6+ cells.

[0065] Example 4—Intra-Assay Precision

[0066] The intra-assay precision of the method was evaluated from four replicates from Analyst 1, Day 1, and Instrument 1. Table 3 shows the pS6 + FC and alpha beta TCR + Cell data.

[0067] Table 3. Targeting pS6 + FC and alpha beta TCR + Intra-assay precision of cells

[0068]

[0069]

[0070] In targeting FC and alpha beta TCR + Cells were stained with a panel of unstimulated and stimulated samples from four replicates of the FCRx final product, pS6 + The %CV of the cells was ≤30% and met the acceptance criteria.

[0071] Example 5 - Intermediate Accuracy

[0072] The intermediate precision of the method was evaluated from data generated by two analysts on two separate flow cytometers over two days. Table 4 shows the pS6 + FC and alpha beta TCR + Cell data.

[0073] Table 4. Intermediate accuracy for pS6+FC and alpha beta TCR+ cells

[0074]

[0075]

[0076] *nd = No data (see deviation 2)

[0077] %CV of ten or twelve replicates of FCRx final product cells analyzed by two analysts using two cytometers on two days for pS6 + FC (unstimulated) was 52.4%, for pS6+ FC (stimulated) was 17.9%, for pS6 + alphabeta TCR + cells (unstimulated) was 36.2% and for pS6 + alpha beta TCR + Cells (stimulated) was 14.2%. Analyst 2 Day 1 results showed lower FC and %pS6+ for both alpha beta TCR+ unstimulated cells compared to both FC and %pS6+ for alpha beta TCR+ unstimulated cells for both Analyst 1 Day 1 and Day 2. There was no acceptance criterion for intermediate precision, but data were reported as found.

[0078] Example 6—Linearity of pS6

[0079] The linearity of the pS6 assay was determined by serially diluting stimulated cells stained for FC and pS6 with stimulated cells stained for FC only. The mean of expected % phosphorylation was plotted as the independent variable against % phosphorylation as the dependent variable, and linear regression analysis using the equation y = ax + b was applied (Table 5, Figure 5 , Table 6).

[0080] Table 5. Summary of FC pS6+ linear data

[0081] <![CDATA[Expected FC% pS6 + cells]]> 62.10 31.05 15.53 7.76 3.88 1.94 0.97 0.49 Repeat 1 64.07 34.58 18.12 10.69 5.87 3.79 3.11 3.06 Repeat 2 61.28 33.59 18.31 10.75 7.36 4.20 3.78 2.60 Repeat 3 60.96 31.86 18.01 10.31 5.89 4.51 3.40 3.01 average value 62.10 33.34 18.15 10.58 6.37 4.17 3.43 2.89 SD 1.711 1.377 0.152 0.239 0.855 0.361 0.336 0.252 %CV 2.8 4.1 0.8 2.3 13.4 8.7 9.8 8.7 % Recovery 100 107.4 116.9 136.3 164.2 214.7 353.5 595.7 Average (minus background) 62.10 31.02 15.82 8.26 4.05 1.84 1.10 0.56 Recovery (minus background) 100.0 99.9 101.9 106.4 104.3 94.8 113.7 116.1

[0082] <![CDATA[pS6 - Sample (background)]]> <![CDATA[pS6 + Percentage of cells in the marker region]]> Repeat 1 2.19 Repeat 2 2.18 Repeat 3 2.61 average value 2.33

[0083] To determine the detection of pS6 + Linearity of the assay for cells not stained for pS6 (pS6 - ) was used to dilute the stimulated sample of pS6 + Due to the autofluorescence of cells, the + The percentage of cells captured approximately 2.33% of pS6 in the marker region - cells. Therefore, this is reduced from the overall average pS6 + The mean value (minus background) was subtracted from the percentage results and used to assess the linearity of the assay.

[0084] Table 6. Linear fitting data of FC pS6+ cells

[0085] parameter Acceptance criteria result Pass / Fail Slope (a) For reference only 0.9976 not applicable Intercept(b) For reference only 0.1668 not applicable Correlation coefficient ≥0.90 0.9999 pass

[0086] Example 7—Robustness or Sample Stability

[0087] The stability of pS6 staining was evaluated by a holding time study using cryopreserved FCRx final product samples. The samples were thawed, stained with the FC panel and pS6, and then divided into three independent aliquots. One aliquot was resuspended in BD staining buffer and analyzed on a flow cytometer (time 0 minutes, T0). Additional aliquots were fixed in 4% paraformaldehyde on ice and tested 15 minutes after fixation (T15min) and 20 hours after storage at 2°C to 8°C (T20 hours). Data from T15min were compared to the T0 time point, and data from the T20 hour time point were compared to the T15min time point to derive % pS6 + The changes in FC were calculated as % difference (% DIFF) (Table 7). + Cell sets and pS6-stained samples were refrigerated overnight in BD staining buffer and reanalyzed the next day (T21 hours). Due to low sample amounts remaining after initial analysis, these samples were pooled and reanalyzed as a single sample. Data from the T21 hour time point were compared to the average T0 time point to derive % pS6 + FC, %pS6 + alpha beta TCR + DIFF (Table 8).

[0088]

[0089] The exact time that the samples were stored was based on the start time of the sample analysis on the FACSCalibur, which was recorded in the electronic list mode file.

[0090] Table 7. pS6 + Stability data of FC (fixed samples)

[0091]

[0092] Table 8. pS6 + Stability data of FC (BD staining buffer sample)

[0093]

[0094] Table 9. pS6 + αβTCR + Stability data (BD staining buffer sample)

[0095]

[0096]

[0097] Samples stored in 2% paraformaldehyde showed pS6 in both unstimulated and stimulated samples + However, samples fixed for 20 h refrigerated had comparable levels of pS6 compared to samples fixed 15 min after fixation. + cell.

[0098] Samples stored overnight in BD staining buffer had comparable levels of pS6 compared to the same samples analyzed the previous day. + FC and pS6 + alpha beta TCR + cell.

[0099] Example 8—Range and Limit of Quantitation

[0100] The pS6 phosflow potency assay demonstrated that panels with FC staining had as low as 0.56% pS6 + The linearity of the cells is acceptable with precision. Since FC is typically smaller than alpha beta TCR + Since the FC panel was used to determine the linearity of pS6, it was applied to FC and alpha beta TCR. + Cells were tested for pS6 + The upper range of cells was 62.10%, which is the highest in the undiluted pS6 used for this assay. + The assay had a precision of 2.8% CV for the three replicates tested. Therefore, it can be assumed that pS6 + Final products with cell frequencies higher than those tested in this assessment will also exhibit acceptable linearity, as higher event frequencies show statistically lower variability. Thus, the range for the pS6phosflow assay is 0.56% to 100% pS6 + cells, with a LOQ of 0.56%.

[0101] Example 9—Threshold of potency

[0102] The assay was evaluated using a representative batch of FCRx final product, where multiple vials of test material were thawed and analyzed over the three days of testing. The pS6 potency assay requires specific criteria to be applied to both FC and alpha beta TCR + Phosphorylation of pS6 in cells can be used to determine whether the cells are viable. This can be done by comparing pS6 in stimulated samples to that in unstimulated samples. + The total increase in cells (pS6 +Percent stimulated minus pS6 + The percentage of unstimulated cells) or by calculating the stimulation factor (pS6 + Percent stimulated / pS6 + The percentage of unstimulated samples was measured by comparing pS6 in stimulated samples with that in unstimulated samples. + The results of the precision test were evaluated for both threshold determination methods and are summarized in Tables 10 and 11. The results for Analyst 2 Day 1 are omitted because they are likely outliers, and the results for Analyst 2 Day 2 are omitted, where duplicate unstimulated samples were not analyzed, as detailed in Deviation 2.

[0103] Table 10. Potency Thresholds – FC

[0104]

[0105] Total pS6 of FC + Increased to 49.75% pS6 + cells and the stimulation factor was 2.89. SD, standard deviation; CV, coefficient of variation

[0106] Table 11. Potency thresholds – alpha beta TCR+ cells

[0107]

[0108]

[0109] αβTCR + Total pS6 in cells + Increased to 76.68% pS6 + cells and the stimulation factor was 17.78.

[0110] Example 10—Deviations from Validation Protocol

[0111] There are two kinds of deviations from validation schemes.

[0112] Deviation 1

[0113] The CO2 incubator used in the assessment was not IQOQPQ. During the assay assessment activity, the incubator temperature and CO2 were monitored using the readout on the incubator. In addition, temperature and CO2 were monitored using a calibrated thermometer and temperature probe and Fyrite kit before and after the assessment test activity. All temperature and CO2 readings were within the required operating specifications of the incubator, and the cells were stimulated and expressed pS6, indicating that the incubator was operating under appropriate conditions. Therefore, this deviation has no impact on the quality or integrity of the data.

[0114] Deviation 2

[0115] Analyst 2 did not have enough cells to prepare two replicates for Day 2 intermediate precision. The replicates of unstimulated cells for FC and alpha beta TCR+ cells were eliminated. Replicate stimulated cells were prepared using 300 μL of sample per tube and the amount of antibody used for cell surface staining was adjusted accordingly. An overall evaluation of intermediate precision was performed using n=10 samples of unstimulated cells and n=12 samples of stimulated cells. Therefore, this deviation had no impact on the quality or integrity of the data.

[0116] Example 11 - Discussion and Conclusion

[0117] The results of the evaluation tests showed that the pS6 antibody used in the phosflow potency assay was selective. - pS6AF647 antibody showed a positive peak with fluorescence separation of more than 1 log when comparing cell populations. pS6 phosphorylation was increased in all stimulated samples compared to unstimulated controls. Detection of FC and alpha beta TCR + The competence of the cells was not compromised by the intracellular phosflow staining protocol, and thus phosphorylation of pS6 was quantified in both cell subpopulations. These data suggest that fluorochrome-conjugated antibody clones recognizing specific cell surface antigens and pS6 can be used in combination in the pS6 phosflow potency assay.

[0118] The pS6phosflow assay demonstrated intra-assay precision of 4.8% CV and 0.8% CV for unstimulated and stimulated FC group samples, respectively, and + The intra-assay precision for the cell panel samples was 18.7% CV and 1.4% CV, respectively. These data were within the acceptance criteria of ≤30% CV. The intermediate precision measured by two analysts using two cytometers on two days was 52.4% CV and 17.9% CV for unstimulated and stimulated FC, respectively, and 1.6% CV for unstimulated and stimulated alpha beta TCR. + 36.2% CV and 14.2% CV, respectively. There was no acceptance criterion for intermediate precision and it is reported as found. However, we did observe a lower pS6 for Analyst 2 Day 1 for the precision test compared to Analyst 1 Day 1 and Day 2 and Analyst 2 Day 2 results. +Percent results. This was determined to be due to insufficient resuspension of cells during the pS6 staining step and indicated that there were key steps in the assay procedure that could contribute to assay variability. Although the intermediate precision of the unstimulated samples was higher (36.2% to 52.4% CV), the stimulated samples showed an intermediate precision of 14.2% CV to 17.9% CV. This represents a batch of FCRx final products and will require further evaluation of the variability of the assay using additional batches of final products to determine the overall variability between donors and manufacturing processes and the variability that may be introduced during the thawing procedure of the frozen test samples.

[0119] The assay demonstrated high sensitivity based on correlation coefficients ≥ 0.90, replicate CV ≤ 30% and pS6 as low as 0.56%. + The linearity of the recovery is within ±30% of the expected value for cells. The upper limit of linearity depends on the individual pS6 present in the test material. + The relative frequency of the cell population, which for the linearity test was 62.10% pS6 + Therefore, it can be assumed that pS6 + Final products with cell frequencies higher than those tested in this assessment will also exhibit acceptable linearity, as higher event frequencies show statistically lower variability. Therefore, linearity and range can be assumed to be from 0.56% pS6 + Cells until 100% pS6 + Linearity was assessed using only the FC group, as this subset typically has more alpha beta TCRs than + These data will therefore be used to compare the frequency of events in the FC and alpha beta TCR + A linear standard of pS6 phosphorylation was applied in both cells.

[0120] Since there is no + Cell accuracy was assessed using commercially available control cells, therefore accuracy was assessed from the expected cell recovery determined during linearity testing. + The neat sample of cells had 62.10% pS6 + cells and were therefore assumed to be nominal. + The actual recovery of cells is compared to the expected results and the accuracy of the measurement is determined. Based on the linearity results, the accuracy within ±30% of the nominal value was demonstrated as low as 0.56% pS6 + FC, which is the specified LOQ for the assay. Therefore, these data indicate that this method is effective for detecting pS6 + FC and alpha beta TCR +Cells are accurate.

[0121] Sample stability was tested for samples refrigerated overnight in BD staining buffer and also for samples stored in cell fixative (2% paraformaldehyde). All cells were fixed after the surface staining and stimulation steps in the pS6 staining protocol, but this robustness evaluation assessed final sample storage in BD staining buffer or storage in 2% paraformaldehyde fixative, depending on the method. For FC samples stored in fixative, 15 min of fixation resulted in a 1.5% decrease in pS6 compared to samples stored in BD staining buffer. + Cell loss was as high as 31.3%. However, subsequent storage of samples in a refrigerator for 21 hours showed no additional pS6 + Cell loss. For samples stored refrigerated in BD staining buffer, 51.1% and 1.3% of pS6 were expressed in unstimulated and stimulated FC samples, respectively. + Loss of cells. Alpha beta TCR stored in BD staining buffer + Cell samples showed a maximum of 6.15% pS6 after 21 h storage in BD staining buffer + These data suggest that pS6phosflow assay samples should be run on a flow cytometer the same day they are prepared.

[0122] By comparing FC and alpha beta TCR + Both cells will be stimulated with pS6 + The percentage of cells expressing pS6 in the unstimulated sample + The percentage of cells was compared to evaluate the threshold of potency. FC showed 49.75% pS6 after stimulation + The total increase in cell percentage was 2.89, as well as a factorial increase of 2.89. alpha beta TCR + Cells showed 76.68% pS6 after stimulation + There was an overall increase in cell percentage and a factorial increase of 17.78. For the batches of FCRx final product tested, alpha beta TCR was expressed compared to FC. + Cells showed greater pS6 after stimulation + Phosphorylation, indicating that each cell type will need specific standards for the threshold value of effectiveness. The assay method assessment has only utilized a batch of FCRx final products, and some variability was observed between different vials of the same batch when thawing and analyzing, as well as the variability between analysts. Therefore, the following threshold values ​​of effectiveness (Table 12) are proposed based on the data from the assessment, and the data collected from the analysis of other FCRx final product batches from research, Phase II clinical manufacturing and assay method validation are further evaluated and improved.

[0123] Table 12. Potency Thresholds

[0124]

[0125] This method evaluates FC and alpha beta TCR in the final product of FCRx + The cell potency method was found to be qualified. The assay was selective, accurate, and precise, with a limit of quantification of 0.56% pS6 + cells and ranged from 0.56% to 100% pS6 + Cells. Samples should be analyzed on the day they are prepared.

[0126] Example 12 - Clinical Application

[0127] Frozen vials of the final product were thawed and the function or potency of the T cells and FC in the final product was determined using a potency assay. These results correlated with a cell viability assay using 7AAD and trypan blue.

[0128] It should be understood that although various aspects have been described herein, the foregoing description of the various aspects is intended to illustrate and not to limit the scope of the method and composition of matter. Other aspects, advantages, and modifications are within the scope of the appended claims.

[0129] Disclosed are methods and compositions that can be used for the disclosed methods and compositions, methods and compositions that can be used in conjunction with the disclosed methods and compositions, methods and compositions that can be used to prepare the disclosed methods and compositions, or methods and compositions as products of the disclosed methods and compositions. These and other materials are disclosed herein, and it should be understood that combinations, subgroups, interactions, groups, etc. of these methods and compositions are disclosed. That is, although there may not be explicit disclosures specifically mentioning each of the various individual and collective combinations and arrangements of these compositions and methods, each is specifically contemplated and described herein. For example, if a composition of a specific substance or a specific method is disclosed and discussed, and a number of compositions or methods are discussed, each combination and arrangement of the compositions and methods will be specifically considered unless there is an explicit statement to the contrary. Likewise, any subgroup or combination of these is also specifically contemplated and disclosed.

Claims

1. A method for determining the potency of a sample comprising facilitating cells (FC) and / or alpha beta TCR+ T cells, the method comprising: contacting a sample comprising FC and / or alpha beta TCR+ T cells with a mitogenic stimulus; and determining the number of FC and / or alpha beta TCR+T cells in the sample whose ribosomal S6 protein (S6) is phosphorylated (pS6); wherein the number of FC and / or alpha beta TCR+T cells in which the ribosomal S6 protein is phosphorylated (pS6) in the sample indicates the potency of the FC and / or alpha beta TCR+T cells in the sample, respectively, The method further comprises determining whether a therapeutic cell composition comprising FC and / or alpha beta TCR+ T cells is stable during and / or after storage.

2. A method for determining the potency of a sample comprising facilitating cells (FC) and / or alpha beta TCR+ T cells, the method comprising: contacting a sample comprising FC and / or alpha beta TCR+ T cells with a mitogenic stimulus; and determining the number of FC and / or alpha beta TCR+T cells in the sample whose ribosomal S6 protein (S6) is phosphorylated (pS6); wherein the number of FC and / or alpha beta TCR+T cells in which the ribosomal S6 protein is phosphorylated (pS6) in the sample indicates the potency of the FC and / or alpha beta TCR+T cells in the sample, respectively, The stability of the FC and / or alpha beta TCR+ T cells after preparation and before administration to a patient, during storage and / or after storage is thereby quantified.

3. The method according to claim 1 or 2, wherein the sample comprises 100,000 to 2,000,000 FC and / or alpha beta TCR+ T cells.

4. The method according to claim 1 or 2, wherein the mitogenic stimulus is selected from the group consisting of phorbol 12-myristate 13-acetate (PMA) with ionomycin, phytohemagglutinin (PHA), concanavalin A (conA) and pokeweed mitogen (PWM).

5. The method of claim 1 or 2, wherein the sample is contacted with the mitogenic stimulus for a period of 5 minutes to 60 minutes.

6. The method of claim 1 or 2, wherein the sample is contacted with the mitogenic stimulus for a period of 20 minutes to 30 minutes.

7. The method according to claim 1 or 2, wherein the number of FC and / or alpha beta TCR+T cells in which the ribosomal S6 protein is phosphorylated (pS6) in the sample is determined using a fluorescently labeled antibody against pS6. The method of claim 7 , wherein the binding of the fluorescently labeled antibody is detected using FACS.

9. The method of claim 1 or 2, wherein at least 30% of the ribosomal S6 protein of the FC in the sample is phosphorylated (pS6).

10. The method of claim 1 or 2, wherein at least 30% of the alpha beta TCR+ T cells in the sample have ribosomal S6 proteins that are phosphorylated (pS6).

11. The method according to claim 1 or 2, wherein the method is performed before freezing the FC and / or alpha beta TCR+ T cells.

12. The method according to claim 1 or 2, wherein the method is performed on frozen FC and / or alpha beta TCR+ T cells.

13. The method of claim 1 or 2, wherein storing comprises cryopreservation.